Citadel Advisors
THNR

Citadel Advisors’s Amplify Weight Loss Drug & Treatment ETF THNR Stock Holding History

Citadel Advisors’s Portfolio THNR Stock Details THNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$670K Buy
+27,241
New +$694K ﹤0.01% 8592

Other funds holding THNR

GS
GTS Securities New York $2.83B AUM 21.76% 1-Year Est. Return
GFA
Godfrey Financial Associates Glenmont, New York $117M AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Citadel Advisors's THNR Position: Q1 2026 in Review

Citadel Advisors opened a new position in Amplify Weight Loss Drug & Treatment ETF (THNR) in Q1 2026: 27,241 shares worth $670K. The stake represents ﹤0.01% of the portfolio and ranks #8592 among its holdings.

4 funds tracked by Wall St. Rank hold THNR as of Q1 2026.

  • Citadel Advisors held 27,241 shares of Amplify Weight Loss Drug & Treatment ETF worth $670K as of Q1 2026.
  • Amplify Weight Loss Drug & Treatment ETF was a new Citadel Advisors position in Q1 2026.
  • Amplify Weight Loss Drug & Treatment ETF made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #8592 holding.
  • 4 funds tracked by Wall St. Rank held Amplify Weight Loss Drug & Treatment ETF as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.